Gabriel I. Barbash
About
Gabriel I. Barbash is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Gabriel I. Barbash has authored 65 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Cardiology and Cardiovascular Medicine, 23 papers in Surgery and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gabriel I. Barbash's work include Acute Myocardial Infarction Research (44 papers), Coronary Interventions and Diagnostics (13 papers) and Cardiac Imaging and Diagnostics (12 papers). Gabriel I. Barbash is often cited by papers focused on Acute Myocardial Infarction Research (44 papers), Coronary Interventions and Diagnostics (13 papers) and Cardiac Imaging and Diagnostics (12 papers). Gabriel I. Barbash collaborates with scholars based in Israel, United States and New Zealand. Gabriel I. Barbash's co-authors include Sherry Glied, Harvey D. White, Eric J. Topol, Michaela Modan, Frans Van de Werf, Maarten L. Simoons, Christopher B. Granger, Philip E. Aylward, Paul W. Armstrong and W. Douglas Weaver and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.
In The Last Decade
Gabriel I. Barbash
64 papers receiving 3.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gabriel I. Barbash Israel | 31 | 2.4k | 1.3k | 998 | 400 | 347 | 65 | 3.8k | ||
| Lori Parsons United States | 26 | 2.5k 1.0× | 955 0.8× | 651 0.7× | 355 0.9× | 491 1.4× | 44 | 3.6k | ||
| Hal V. Barron United States | 34 | 4.6k 1.9× | 1.6k 1.3× | 1.2k 1.2× | 439 1.1× | 332 1.0× | 81 | 6.1k | ||
| Richard M. Steingart United States | 37 | 3.1k 1.3× | 761 0.6× | 1.1k 1.1× | 164 0.4× | 737 2.1× | 140 | 4.9k | ||
| David F. Kong United States | 30 | 2.8k 1.2× | 1.8k 1.4× | 594 0.6× | 179 0.4× | 519 1.5× | 76 | 3.7k | ||
| David van Klaveren Netherlands | 32 | 2.1k 0.8× | 1.8k 1.4× | 753 0.8× | 473 1.2× | 650 1.9× | 121 | 4.5k | ||
| Usman Baber United States | 36 | 3.3k 1.4× | 2.4k 1.9× | 1.0k 1.0× | 282 0.7× | 817 2.4× | 193 | 5.7k | ||
| Frederic S. Resnic United States | 31 | 1.3k 0.5× | 1.1k 0.9× | 376 0.4× | 366 0.9× | 786 2.3× | 99 | 2.9k | ||
| Michael Racz United States | 22 | 1.8k 0.7× | 1.7k 1.3× | 718 0.7× | 405 1.0× | 452 1.3× | 44 | 2.8k | ||
| Gary Walford United States | 30 | 2.5k 1.0× | 2.3k 1.8× | 1.3k 1.3× | 213 0.5× | 477 1.4× | 84 | 3.3k | ||
| Bo Lagerqvist Sweden | 38 | 4.8k 2.0× | 2.5k 2.0× | 2.3k 2.3× | 202 0.5× | 420 1.2× | 103 | 5.8k |
Countries citing papers authored by Gabriel I. Barbash
Since
Specialization
Citations
This map shows the geographic impact of Gabriel I. Barbash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel I. Barbash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel I. Barbash more than expected).
Fields of papers citing papers by Gabriel I. Barbash
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gabriel I. Barbash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel I. Barbash. The network helps show where Gabriel I. Barbash may publish in the future.
Co-authorship network of co-authors of Gabriel I. Barbash
This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel I. Barbash. A scholar is included among the top collaborators of Gabriel I. Barbash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel I. Barbash. Gabriel I. Barbash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Barbash, Gabriel I. & Sherry Glied. (2010). New Technology and Health Care Costs — The Case of Robot-Assisted Surgery. New England Journal of Medicine. 363(8). 701–704.
2.
Schreiber, Shaul, Gedalia Paz, Gabriel I. Barbash, et al.. (2004). Hospital preparedness for possible nonconventional casualties: an Israeli experience. General Hospital Psychiatry. 26(5). 359–366.
3.
Birnbaum, Yochai, Shaun G. Goodman, Aiala Barr, et al.. (2001). Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. The American Journal of Cardiology. 88(8). 842–847.
4.
Herz, Izhak, Boris Strasberg, Samuel Sclarovsky, et al.. (1999). The Prognostic Implications of Negative T Waves in the Leads with ST Segment Elevation on Admission in Acute Myocardial Infarction. Cardiology. 92(2). 121–127.
5.
Birnbaum, Yochai, Izhak Herz, Samuel Sclarovsky, et al.. (1998). Admission clinical and electrocardiographic characteristics predicting an increased risk for early reinfarction after thrombolytic therapy. American Heart Journal. 135(5). 805–812.
6.
Weaver, W. Douglas, Harvey D. White, Robert G. Wilcox, et al.. (1997). Comparisons of Characteristics and Outcomes Among Women and Men with Acute Myocardial Infarction Treated with Thrombolytic Therapy. Survey of Anesthesiology. XLI(3). 147???148–147???148.
7.
Mahaffey, Kenneth W., Christopher B Granger, Cynthia A. Toth, et al.. (1997). Diabetic Retinopathy Should Not Be a Contraindication to Thrombolytic Therapy for Acute Myocardial Infarction: Review of Ocular Hemorrhage Incidence and Location in the GUSTO-I Trial fn1fn1This study was supported by Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology. 30(7). 1606–1610.
8.
Califf, Robert M., Lynn H. Woodlief, Frank E. Harrell, et al.. (1997). Selection of thrombolytic therapy for individual patients: Development of a clinical model. American Heart Journal. 133(6). 630–639.
9.
Barbash, Gabriel I., Jonathan Reiner, H. D. White, et al.. (1995). Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights. Journal of the American College of Cardiology. 26(5). 1222–1229.
10.
Birnbaum, Yochai, et al.. (1995). 790-1 The Admission Electrocardiogram-Characteristics Identifying a Subgroup at Increased Risk for Reinfarction. Journal of the American College of Cardiology. 25(2). 342A–342A.
11.
Birnbaum, Yochai, et al.. (1995). 790-5 Prognostic Significance of Different Patterns of Precordial ST Segment Depression in Inferior Wall Acute Myocardial Infarction. Journal of the American College of Cardiology. 25(2). 343A–343A.
12.
Barbash, Gabriel I., Michaela Modan, Uri Goldbourt, Harvey D. White, & Frans Van de Werf. (1993). Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: Variation by country beyond predictive profile. Journal of the American College of Cardiology. 21(2). 281–286.
13.
Barbash, Gabriel I., Harvey D. White, Michaela Modan, & Frans Van de Werf. (1993). Significance of diabetes mellitus in patients with acute myocardial infraction receiving thrombolytic theraphy. Journal of the American College of Cardiology. 22(3). 707–713.
14.
Barbash, Gabriel I., et al.. (1992). Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: Experience gleaned from the international tissue plasminogen activator/streptokinase mortality trial. Journal of the American College of Cardiology. 20(1). 36–41.
15.
Topol, Eric J., Paul W. Armstrong, Frans Van de Werf, et al.. (1992). Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Journal of the American College of Cardiology. 19(6). 1123–1128.
16.
Shechter, Michael, et al.. (1992). Additional ST segment elevation during the first hour of thrombolytic therapy: An electrocardiographic sign predicting a favorable clinical outcome. Journal of the American College of Cardiology. 20(7). 1460–1464.
17.
Motro, Michael, Gabriel I. Barbash, Hanoch Hod, et al.. (1991). Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction. American Heart Journal. 122(1). 23–26.
18.
Barbash, Gabriel I., Hanoch Hod, Arie Roth, et al.. (1990). Repeat infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. Journal of the American College of Cardiology. 16(4). 779–783.
19.
Roth, Arie, Hylton I. Miller, Edo Kaluski, et al.. (1990). Early Thrombolytic Therapy Does Not Enhance the Recovery of the Right Ventricle in Patients with Acute Inferior Myocardial Infarction and Predominant Right Ventricular Involvement. Cardiology. 77(1). 40–49.
20.
Barbash, Gabriel I., Mitchell T. Rabkin, Nancy M. Kane, & Donald S. Baim. (1986). Coronary angioplasty under the prospective payment system: The need for a severity-adjusted payment scheme. Journal of the American College of Cardiology. 8(4). 784–790.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lori Parsons Breakdown of academic impact, for papers by Hal V. Barron Breakdown of academic impact, for papers by Richard M. Steingart Breakdown of academic impact, for papers by David F. Kong Breakdown of academic impact, for papers by David van Klaveren Breakdown of academic impact, for papers by Usman Baber Breakdown of academic impact, for papers by Frederic S. Resnic Breakdown of academic impact, for papers by Michael Racz Breakdown of academic impact, for papers by Gary Walford Breakdown of academic impact, for papers by Bo Lagerqvist